论文部分内容阅读
目的探讨西帕依麦孜彼子口服液联合甲磺酸多沙唑嗪缓释片治疗慢性前列腺炎的临床疗效及安全性。方法将120例慢性前列腺炎患者随机分为对照组和治疗组,对照组(n=60)单用甲磺酸多沙唑嗪缓释片口服治疗,治疗组(n=60)予以口服甲磺酸多沙唑嗪缓释片并联合西帕依麦孜彼子口服液进行治疗,连续口服4w。比较两组患者治疗总有效率,观察两组患者治疗前后美国国立卫生研究院慢性前列腺炎症状评分(NIHCPSI)相关指标变化、治疗前后前列腺液白细胞(WBC)数目变化、最大尿流率及平均尿流率变化,并记录不良反应的发生情况。结果治疗组总有效率(88.33%)显著高于对照组总有效率(61.67%),差异有统计学意义(P<0.05)。两组患者治疗后的NIH-CPSI评分均优于治疗前,其中治疗组疼痛症状、排尿症状、生活质量评分及总评分均低于对照组,差异有统计学意义(P<0.05)。两组治疗后WBC计数均低于其治疗前WBC计数,治疗组治疗后WBC计数明显低于对照组治疗后WBC计数,差异有统计学意义(P<0.05)。两组患者治疗后最大尿流率及平均尿流率均明显高于治疗前,治疗组治疗后最大尿流率及平均尿流率显著高于对照组治疗后,差异均有统计学意义(P<0.05)。两组患者均未出现明显药物不良反应。结论西帕依麦孜彼子口服液联合多沙唑嗪片联合治疗慢性前列腺炎临床疗效显著,无明显不良反应,临床上应用可靠安全,具有重要的临床研究价值。
Objective To investigate the clinical efficacy and safety of Xipayiti Mazi Pizi oral liquid combined with doxazosin mesylate sustained-release tablets in the treatment of chronic prostatitis. Methods 120 patients with chronic prostatitis were randomly divided into control group and treatment group. The control group (n = 60) was treated with doxazosin mesylate sustained-release tablets orally. The treatment group (n = 60) Acid Doxazosin sustained release tablets combined with Xipay Mai Zi Pizi oral solution for continuous oral 4w. The total effective rate was compared between the two groups before and after treatment. The changes of NIHPSI scores before and after treatment, the number of prostatic fluid leukocytes (WBC) before and after treatment, the maximum urinary flow rate and the average urine Flow rate changes, and record the occurrence of adverse reactions. Results The total effective rate (88.33%) in the treatment group was significantly higher than that in the control group (61.67%), the difference was statistically significant (P <0.05). The NIH-CPSI scores of the two groups were better than those before treatment. The pain symptom, urination symptom, quality of life score and total score of the treatment group were lower than the control group, the difference was statistically significant (P <0.05). The WBC counts in both groups were lower than those before treatment, the WBC counts in the treatment group were significantly lower than those in the control group after treatment, the difference was statistically significant (P <0.05). After treatment, the maximal urinary flow rate and mean urinary flow rate in both groups were significantly higher than those before treatment, and the maximum urinary flow rate and average urinary flow rate in the treatment group were significantly higher than those in the control group after treatment (P <0.05). No obvious adverse drug reactions occurred in both groups. Conclusion Xipayi Mazi Pizi oral combination of doxazosin tablets in the treatment of chronic prostatitis clinical efficacy was significant, no obvious adverse reactions, clinical application of reliable and safe, has important clinical research value.